SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

REGENXBIO Inc.
Date: June 23, 2025 · CIK: 0001590877 · Accession: 0001193125-25-144857

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288053

Date
June 23, 2025
Author
By
Form
CORRESP
Company
REGENXBIO Inc.

Letter

Re: REGENXBIO Inc. (the “Company”)

June 23, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Attn: Doris Stacey Gama

Registration Statement Filed on Form S-3 (the “Registration Statement”)

File No. 333-288053 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on June 25, 2025, or as soon as practicable thereafter. Please contact Matthew C. Franker of Covington & Burling LLP at (202) 662-5895 or mfranker@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Franker by telephone when this request for acceleration has been granted.

Respectfully,
REGENXBIO Inc.

Show Raw Text
CORRESP
 1
 filename1.htm

 CORRESP

 June 23, 2025
 Via EDGAR U.S. Securities and Exchange Commission
 Division of Corporation Finance 100 F Street, N.E.
 Washington, D.C. 20549

 Attn:
 Doris Stacey Gama

 Re:
 REGENXBIO Inc. (the “Company”)

  
 Registration Statement Filed on Form S-3 (the “Registration
Statement”)

  
 File No. 333-288053
 Ladies and Gentlemen: Pursuant to
Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on June 25, 2025, or as
soon as practicable thereafter. Please contact Matthew C. Franker of Covington & Burling LLP at
 (202) 662-5895 or mfranker@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Franker by telephone when this request for acceleration has been granted.

 Respectfully,

 REGENXBIO Inc.

 By:

 /s/ Patrick Christmas

 Name:

 Patrick Christmas

 Title:

 Executive Vice President, Chief Legal
Officer

 cc:
 Matthew C. Franker, Covington & Burling LLP